



RESEARCH ARTICLE

REVISED

# Multi-repeat sequences identification using genome mining techniques for developing highly sensitive molecular diagnostic assay for the detection of *Chlamydia trachomatis*

[version 2; peer review: 2 approved]

Clement Shiluli<sup>1</sup>, Shwetha Kamath<sup>2</sup>, Bernard N. Kanoi<sup>1</sup>, Racheal Kimani<sup>1</sup>, Michael Maina<sup>1</sup>, Harrison Waweru<sup>1</sup>, Moses Kamita<sup>1</sup>, Ibrahim Ndirangu<sup>1</sup>, Hussein M. Abkallo<sup>3</sup>, Bernard Oduor<sup>3</sup>, Nicole Pamme<sup>4</sup>, Joshua Dupaty<sup>5</sup>, Catherine M. Klapperich<sup>5</sup>, Srinivasa Raju Lolabattu<sup>2</sup>, Jesse Gitaka<sup>1</sup>

<sup>1</sup>Centre for Research in Infectious Diseases, College of Graduate Studies and Research, Mount Kenya University, Thika, Kiambu County, Kenya

<sup>2</sup>Division of Research and Development, Jigsaw Bio Solutions Private Limited, Bangalore, India

<sup>3</sup>Animal and Human Health Program, International Livestock Research Institute, Nairobi, Nairobi County, Kenya

<sup>4</sup>Department of Materials and Environmental Chemistry, Stockholm University, Stockholm, Stockholm County, Sweden

<sup>5</sup>Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA

v2 First published: 08 Jan 2024, 7:2

<https://doi.org/10.12688/openresafrica.14316.1>

Latest published: 09 May 2024, 7:2

<https://doi.org/10.12688/openresafrica.14316.2>

## Abstract

*Chlamydia trachomatis* (*C. trachomatis*) is a common sexually transmitted infection (STI). In 2019, the World Health Organization reported about 131 million infections. The majority of infected patients are asymptomatic with cases remaining undetected. It is likely that missed *C. trachomatis* infections contribute to preventable adverse health outcomes in women and children. Consequently, there is an urgent need of developing efficient diagnostic methods. In this study, genome-mining approaches to identify identical multi-repeat sequences (IMRS) distributed throughout the *C. trachomatis* genome were used to design a primer pair that would target regions in the genome. Genomic DNA was 10-fold serially diluted (100pg/µL to 1×10-3pg/µL) and used as DNA template for PCR reactions. The gold standard PCR using 16S rRNA primers was also run as a comparative test, and products were resolved on agarose gel. The novel assay, *C. trachomatis* IMRS-PCR, had an analytical sensitivity of 4.31 pg/µL, representing better sensitivity compared with 16S rRNA PCR (9.5 fg/µL). Our experimental data demonstrate the successful development of lateral flow and isothermal assays for detecting *C. trachomatis* DNA with potential use in field settings. There is a

## Open Peer Review

### Approval Status

1 2

#### version 2

(revision)

09 May 2024



view



#### version 1

08 Jan 2024



view



view

1. Shehu Awandu<sup>1</sup>, Jaramogi Oginga Odinga

University of Science and Technology, Bondo, Kenya

2. Tom Were<sup>1</sup>, Masinde Muliro University of

Science and Technology, Kakamega, Kenya

Any reports and responses or comments on the article can be found at the end of the article.

potential to implement this concept in miniaturized, isothermal, microfluidic platforms, and laboratory-on-a-chip diagnostic devices for reliable point-of-care testing.

### Keywords

Identical Multi-Repeat Sequences, Chlamydia trachomatis, Isothermal assays

**Corresponding authors:** Clement Shiluli ([clementshiluli@gmail.com](mailto:clementshiluli@gmail.com)), Srinivasa Raju Lolabattu ([raju@jigsawbio.com](mailto:raju@jigsawbio.com)), Jesse Gitaka ([jgitaka@mku.ac.ke](mailto:jgitaka@mku.ac.ke))

**Author roles:** **Shiluli C:** Conceptualization, Data Curation, Formal Analysis, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Kamath S:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization; **N. Kanoi B:** Data Curation, Investigation, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Kimani R:** Data Curation, Investigation, Methodology, Supervision, Visualization, Writing – Original Draft Preparation; **Maina M:** Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation; **Waweru H:** Data Curation, Methodology, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kamita M:** Data Curation, Investigation, Methodology, Project Administration, Software, Supervision, Visualization, Writing – Original Draft Preparation; **Ndirangu I:** Data Curation, Methodology, Project Administration, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **M. Abkallo H:** Conceptualization, Data Curation, Investigation, Methodology, Supervision, Validation, Visualization, Writing – Original Draft Preparation; **Oduor B:** Investigation, Methodology, Project Administration, Resources, Software, Validation, Visualization, Writing – Original Draft Preparation; **Pamme N:** Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Dupaty J:** Data Curation, Investigation, Methodology, Software, Validation, Writing – Original Draft Preparation; **M. Klapperich C:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Software, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Raju Lolabattu S:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Gitaka J:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by the African Academy of Sciences (AAS) through a Future Leaders African Independent Researchers (FLAIR) Scheme (FLR\IR1\201314) awarded to JG.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2024 Shiluli C *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Shiluli C, Kamath S, N. Kanoi B *et al.* **Multi-repeat sequences identification using genome mining techniques for developing highly sensitive molecular diagnostic assay for the detection of *Chlamydia trachomatis* [version 2; peer review: 2 approved]** Open Research Africa 2024, 7:2 <https://doi.org/10.12688/openresafrica.14316.2>

**First published:** 08 Jan 2024, 7:2 <https://doi.org/10.12688/openresafrica.14316.1>

## **REVISED Amendments from Version 1**

On behalf of the authors, I am delighted to express my gratitude to the reviewers and editors of the Open Research Africa Journal. Indeed, the revised version of our manuscript has been greatly improved after considering all the suggestions and comments. The authors were asked to state the additional advantages of the CT-IMRS PCR assay as compared to conventional PCR techniques and the adverse clinical outcomes of *Chlamydia trachomatis* infection in women. The authors included advantages of the CT-IMRS (Refer to the introduction section). Also, the overall turn-around time of the CT-IMRS was mentioned. The authors were also asked to describe the specific treatment that the participant who were recruited into the study were given. Treatment regimens for the participant was included in the revised version of the manuscript (method section). The clinical samples that were used to validate the CT-IMRS assay were mentioned in the result section of the revised manuscript. The authors were also requested to rephrase figure captions for clarity. No new Figures or Tables have been added to the new version. The authors have also included the specificity and sensitivity of the CT-IMRS assay. The expected band sizes for the CT-IMRS primers have also been stated as suggested by the reviewers. The authors were also asked to mention the major limitation of the study. This section has been included. Some more edits have also been addressed appropriately.

**Any further responses from the reviewers can be found at the end of the article**

## **Introduction**

*Chlamydia trachomatis* (*C. trachomatis*) is among the most common sexually transmitted infections (STIs) that lead to adverse birth and neonatal outcomes such as pre-term labor and low birth weight infants<sup>1</sup>. It is, therefore, most likely that undiagnosed maternal *C. trachomatis* infections may lead to unavoidable adverse health outcomes in women and children worldwide, for example, salpingitis, endometritis, tubo-ovarian abscesses, pelvic peritonitis, blocked fallopian tubes and perihepatitis<sup>2</sup>. During delivery, the risk of mother-to-child transmission of *C. trachomatis* increases<sup>3</sup>. Most patients with *C. trachomatis* infections are asymptomatic, and these cases remain undetected and untreated, further complicating the management of infected cases in most countries<sup>4</sup>. In 2019 the World Health Organization (WHO) reported about 131 million infections of *C. trachomatis* globally<sup>5</sup>.

Traditional methods of *C. trachomatis* testing include cervical cytological examination using Papanicolaou (Pap) smears<sup>6</sup>. However, these techniques have many challenges, such as technical difficulties during cultures, labor intensiveness, increased turnaround time, and high cost. *C. trachomatis* infections are diagnosed by indirect and direct methods<sup>7</sup>.

Direct methods detect the presence of *C. trachomatis* in localized infections<sup>7</sup>. These methods include culture, antigen tests (Enzyme Immuno Assays (EIA), Direct Fluorescent Antibody (DFA) tests, immune chromatographic tests, Rapid Detection Tests (RDTs), and Nucleic Acid Amplification Tests (NAATs))<sup>7</sup>. Indirect methods are specific to *C. trachomatis* antibodies and

are used for diagnostic evaluation of chronic or invasive infection (Pelvic Inflammatory Disease and lymphogranuloma venereum) and post-infectious complications, like sexually acquired reactive arthritis (SARA)<sup>7</sup>.

Direct detection methods, such as NAATs, have several advantages. They use polymerase chain reaction (PCR) and use fluorescent-labeled probes to identify amplification products in real-time, and these reduce the turn-around time<sup>8</sup>. Studies have also shown that *C. trachomatis* PCR using DNA extracted from conjunctival swabs can achieve a detection limit of up to 100 plasmid copies<sup>9</sup>.

Other NAATs, such as ligase chain reaction and transcription mediated amplification, are also specific and sensitive in the screening of *C. trachomatis* in patient samples<sup>10</sup>. Results of these tests can be generated in a few hours when coupled with automated nucleic acid extraction techniques.

However, NAATs such as the Abbot Real-Time CT/NG requires stringent sample transport and storage conditions<sup>11</sup>. For example, to achieve accurate and reliable results, samples from asymptomatic women must be stored between 2°C and 30°C and processed within 14 days after collection<sup>11</sup>. Symptomatic women's specimens must be thawed, frozen, and stored at the same temperature range<sup>11</sup>. These conditions may be challenging, mainly in resource-limited countries where refrigeration facilities are unavailable, especially during specimen collection and transport<sup>12</sup>.

When compared to *C. trachomatis* culture, the DFA has a sensitivity of between 95–100%<sup>13</sup>. However, DFA involves labor-intensive microscopic examination of individual stained specimens, which can be time-consuming when dealing with many samples<sup>13</sup>. Also, highly skilled and experienced personnel perform routine microscopic examinations<sup>13</sup>. By contrast, EIAs are suitable for testing of many samples and have sensitivities of 90% as compared to culture, however, they are less accurate than DFA and test results may be false positive<sup>13</sup>.

Thriving *C. trachomatis* culture is dependent on isolated live organisms, and cases identified in clinical samples ranges between 60–80%. In addition, culture sensitivity can be affected by improper specimen sample collection, and transport, storage, toxic material in patient samples, and colonization of cell cultures by opportunistic microorganisms<sup>14</sup>. *C. trachomatis* culture has prolonged turn-around time; it is labor intensive, and different laboratories have various standardization protocols<sup>14</sup>.

Indirect methods used for the identification of *C. trachomatis* are inaccurate in identifying acute infections of the lower reproductive and digestive tract; this is because antibody responses become detected after several weeks to months after an initial infection<sup>14</sup>.

Enzyme linked immuno-sorbent assays that detect bacterial lipopolysaccharide may cross-react with other gram

negative bacteria, which may give false-positive results. The *C. trachomatis* antibody response may be absent or delayed in some patients, which makes many serological tests inaccurate<sup>15</sup>. In addition, most of the *C. trachomatis* infections are asymptomatic and are diagnosed late, resulting in uninterrupted transmission<sup>16</sup>. To manage asymptomatic *C. trachomatis* infections, there is an urgent need to develop efficient methods of diagnosis with appropriate specificity and sensitivity that can be incorporated as part of routine screening programs, can be used to identify new infections and prevent the transmission of *C. trachomatis* cases<sup>17</sup>. In this study, we have developed a highly sensitive molecular method that uses *de novo* genome mining approaches to detect identical multi-repeat sequences (IMRS) in *C. trachomatis* bacterial genome to be used as both isothermal amplification and PCR assays. The assay has a potential for field deployability due to inherent high sensitivity.

## Methods

**Identical Multi-Repeat Sequence (IMRS) genome-mining**  
The primers used in this study were developed using Identical Multi-Repeat Sequence (IMRS) genome mining algorithm. The IMRS algorithm was designed by using the Java Collection Framework by plugging in Google Guava version 23.0-jre (open-source common libraries for Java; <https://github.com/google/guava>, last accessed September 1, 2018). In the *C. trachomatis* IMRS application, the algorithm performs an analysis of the genome to select similar repeating oligonucleotide sequences of various lengths. The algorithm fragments the *C. trachomatis* genome into cross-matching windows of size L and enumerates all fragmented L-mer sequences into a list along with their corresponding positional coordinates on the genome. The repeated L-mers are determined with their exact positions categorized and classified on the basis of the repeat count. The hit counts are then screened by calculating coordinates for a pair of repeat sequences that are next to each other on the *Chlamydia trachomatis* genome and within an amplifiable region for primer generation. The NIH's Basic Local Alignment Search Tool (BLAST; NIH, Bethesda, MD; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>, last accessed July 11, 2019) and the National Center for Biotechnology Information's Primer-BLAST (NCBI, Bethesda, MD; <https://www.ncbi.nlm.nih.gov/tools/primer-blast>, last accessed July 11, 2019) evaluated the specificity of lead pairs and the best pair was then identified. To identify *C. trachomatis* IMRS primers, *C. trachomatis* genome was used as an input for IMRS algorithm; and the primer pair having maximum number of repeats was selected for assay design. BLAST analyses were then performed to ensure that the selected primer pair is specific only for *Chlamydia trachomatis*<sup>18</sup>. The *C. trachomatis* genome (NCBI, NC\_000117.1) was used as a standard to mine repetitive sequences of less than 30 bases that can serve as reverse or forward primers. The Basic Local Alignment Search Tool available from the NIH website was used to determine the primer sets to ascertain

*C. trachomatis* specificity. The resulting primers were predicted to amplify 6 fragment sizes of DNA derived from different regions of the *C. trachomatis* genome as shown in Table 1.

Distribution of primer targets on the *C. trachomatis* genome was determined by the Circos plot version 0.69–9 (Circos; RRID:SCR\_011798).

### *C. trachomatis* genomic DNA preparation

*C. trachomatis* DNA was purchased from the American Type Culture Collection (ATCC) (ATCC® VR-885D™, LOT Number. 70013611) (Manassas, Virginia, USA) at an initial concentration of  $\geq 1 \times 10^5$  genome copies/ $\mu$ L. The original DNA stock concentration was diluted to 100 pg/ $\mu$ L ( $8.92 \times 10^4$  copies/ $\mu$ L) and eventually diluted 100 fold and 10 fold in Tris EDTA buffer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) for the respective PCR assays.

### 16S rRNA PCR

The 16S rRNA PCR assays were performed in a SimpliAmp Thermal Cycler (Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachusetts, USA) in a 25  $\mu$ L reaction volume composed of dNTPs (Thermo Fisher Scientific, Waltham, Massachusetts, USA) (0.2mM), forward (TCCGGAGCGAGTTACGAAGA) and reverse (AATCAATGCCGGGATTGGT) primers (0.01 mM each) (Macrogen, Seoul, South Korea), Taq Hot-Start DNA polymerase (Thermo Fisher Scientific, Waltham, Massachusetts, USA) (1.25 U), and 1  $\mu$ L *C. trachomatis* DNA. The thermocycling parameters were as indicated: 95°C for 3 min; 40 cycles of: 95°C for 30 s, 56°C for 30 s, 72°C for 30 s; and 72°C for 5 min and a final hold step of 4°C<sup>19</sup>. All PCR amplicons were resolved in 1% agarose gel and visualized on a UV Gel illuminator machine (Fison Instruments, Glasgow, United Kingdom) under ethidium bromide (Thermo Fisher Scientific, Massachusetts, USA) staining<sup>19</sup>.

**Table 1. IMRS Primer target regions on the *Chlamydia trachomatis* bacterial genome.** IMRS, identical multi-repeat sequences.

No.	Amplification regions	Expected sequence fragment
1	531375 - 531511	137bp
2	531375 - 531661	287bp
3	531375 - 531814	440bp
4	531525 - 531661	137bp
5	531525 - 531814	290bp
6	531675 - 531814	140bp

### C. trachomatis IMRS PCR

The *C. trachomatis* IMRS assays were carried out in a SimpliAmp Thermal Cycler (Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachusetts, USA) in a 25 µL reaction volume consisting of dNTPs (Thermo Fisher Scientific, Massachusetts, USA) (0.2 mM), forward (TGCTGCTGCTGAT-TACGAGCCGA) and reverse (TGTAGGAGGAGCCTCTT-GAGAA) primers (0.01 mM) (Jigsaw Biosolutions, Bengaluru, India), Taq Hot-Start DNA polymerase (Thermo Fisher Scientific, Massachusetts, USA) (1.25 U) and 1 µL *C. trachomatis* DNA. The thermocycling parameters for *C. trachomatis*-IMRS PCR assay was as indicated: 95°C for 3 min; 40 cycles of: 95°C for 30 s, 50°C for 30 s, 72°C for 30 s; and 72°C for 5 min and a final hold of 4°C. All PCR amplicons were resolved in 1% agarose gel and visualized on a UV Gel illuminator machine (Fison Instruments, Glasgow, United Kingdom) under ethidium bromide (Thermo Fisher Scientific, Massachusetts, USA) staining<sup>19</sup>.

### Isothermal IMRS amplification

The Isothermal IMRS amplification was done in a reaction volume of 25 µL composed of the following *Bst* 2.0 polymerase (640 U/mL) (New England Biolabs, Massachusetts, USA), with 1X amplification buffer, 1.6 µM reverse primer (TGTAGGAGGAGCCTCTTAGAGAA), and 3.2 µM forward primer (TGCTGCTGCTGATTACGAGCCGA) (Jigsaw Biosolutions, Bengaluru, India) with 10 mM dNTPs (Thermo Fisher Scientific, Massachusetts, USA), 0.4 M Betaine (Sigma-Aldrich, Missouri, USA), molecular-grade water and Ficoll (0.4 g/mL) (Sigma-Aldrich, Missouri, USA). Amplification was performed at 56°C for 40 min. PCR amplicons were resolved in 1% agarose gel and visualized on a UV Gel illuminator machine (Fison Instruments, Glasgow, United Kingdom) under ethidium bromide (Thermo Fisher Scientific, Massachusetts, USA) staining<sup>19</sup>.

### Lower limit of detection

To determine the lower limit of detection (LLOD), DNA template was diluted 100-fold from 100 pg/µL ( $8.92 \times 10^4$  copies/µL) to  $10^{-6}$  pg/µL (<1 copies/µL) and 10-fold from 100 pg/µL ( $8.92 \times 10^4$  copies/µL) to  $10^{-2}$  pg/µL (< 1 copies/µL) for the *C. trachomatis* IMRS PCR and gold standard 16S rRNA PCR, respectively. Five replicates of each dilution were then used for the PCR assays. PCR amplicons were resolved in 1% agarose gel and visualized on a UV Gel illuminator machine (Fison Instruments, Glasgow, United Kingdom) under ethidium bromide staining. To calculate the LLOD of the 16S rRNA and IMRS *C. trachomatis* PCR, probit analysis was done by determining the ratio of reactions that were successful to the total number of reactions performed. Similarly, to assess the LLOD for the *C. trachomatis* Isothermal IMRS PCR assay, genomic DNA was diluted 10-fold from a starting concentration of  $1.64 \times 10^6$  copies/µL. Thereafter, the LLOD was calculated as mentioned earlier<sup>19</sup>.

### C. trachomatis-Lateral Flow Assay

To produce a visual read-out signal of amplified products, the *C. trachomatis*-Lateral Flow Assay (*C. trachomatis*-LFA) was performed as follows in a final master mix volume of 25 µL, 2.5 µL annealing buffer, dNTPs and NaCl (1.75 µL), MgSO<sub>4</sub> (1.2 µL), NG 5' biotinylated forward primer (Biotin 5'-“TGCTGCTGCTGATTACGAGCCGA”-3'), *C. trachomatis* Reverse primer, *C. trachomatis* 3' FAM labelled probe (CCAC-CAATACTCTC/-FAM-3'), *C. trachomatis* Digoxin labelled probe, Ficoll 400 (6.25 µL), internal control sequence (2.5 µL), ISO Amp III enzyme mix 2.0 µL, *C. trachomatis* DNA 5µL and molecular grade water 1.45 µL. The LFA strip (Milenia Biotec GmbH, Giessen, Germany) were incubated at 65°C for 1 hour, thereafter, 5 µL of reaction liquid was added to the LFA strip and 2 drops of buffer added<sup>19</sup>.

### Real-time PCR assay

Real-Time PCR assay was performed on the QuantStudio™ 5 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachusetts, USA) as a comparative method<sup>20</sup> for determining the sensitivity of the *C. trachomatis* IMRS and 16S rRNA PCR primers for detecting *C. trachomatis* DNA. The genomic DNA was serially diluted 10-fold starting concentration of  $10^4$  genome copies/µL. The PCR was done in triplicate in a final master mix volume of 10 µL and was composed of the following: 1 µL reverse and forward IMRS primer mix, 5 µL SYBR Green qPCR Master Mix (Thermo Fisher, Massachusetts, USA), 2.5 µL *C. trachomatis* DNA and 1.5 µL molecular grade water. The thermocycling conditions were 50°C for 2 min; 95°C for 10 min; 40 cycles of 95°C for 15 s and 60°C for 30 s.

### Confirmation of *C. trachomatis*-IMRS amplicons using gene cloning

Specificity *C. trachomatis*-IMRS primers was also confirmed using gene cloning. Amplification of *Chlamydia trachomatis* gDNA was done using Assembly IMRS-F (ttccggatggctcgagttt-tcagcaaggattgcctgccTGCTGATTACGAGCCGA) and Assembly IMRS-R (agaatattttaggatcttctagaaagatt GTA**GGAGGAGCCTTTAGAGAA**) primer set. The bold and underlined sequences represent the IMRS primers specific for the *C. trachomatis* genome whereas the non-priming overlap lowercase sequence at the 5'-end of the primers sequence corresponds to the homologous sequences in the vector used for cloning. The PCR products were resolved on 2% agarose to ascertain the size of the fragment and thereafter the PureLink™ PCR purification kit (ThermoFisher) was used for purification. The NEBuilder® HiFi DNA Assembly kit (NEB) was used to ligate the PCR products into pJET1.2 blunt vector (ThermoFisher) following the manufacturer's protocol. The NEBuilder HiFi DNA Assembly product obtained was further transformed into NEB 5-alpha Competent *E. coli* (NEB #C2987, NEB) following the manufacturer's recommendations. Colonies that were transformed were selected randomly, DNA extraction and Sanger-sequencing

done using the universal pJET1.2 forward sequencing primer (cgactcataatgggagccgc) and pJET1.2 reverse sequencing primer (aagaacatcgatttccatggcag). The nucleotides obtained were trimmed and assessed using SnapGene sequence analysis software (Version 6.1 GSL Biotech; available at snapgene.com, RRID:SCR\_015052), alignment performed to determine similarity and or clonal differences and BLAST used assess for similarity with the *C. trachomatis* genomic sequences.

#### Clinical samples

Vaginal swab samples collected from a cohort of women aged between 19 – 49 years participating in an STI study in Nairobi County at the Kenyatta National Hospital (KNH) in 2022 were used to validate the *Chlamydia trachomatis* IMRS PCR method. Enrolled participants provided written informed consent. This study was approved by the KNH Ethics Review Committee on the 13<sup>th</sup> of April 2022 (P928/12/2021). The *C. trachomatis*-16S rRNA PCR method was used to screen for *C. trachomatis* cases. Thereafter, positive clinical samples were used to validate the *C. trachomatis*-IMRS primers. Participants were notified of results directly and confidentially by study staff, and were treated for *C. trachomatis* infection. Patients with persistent symptoms were referred to a molecular laboratory for testing. The following drugs were used, Ceftriaxone, Azithromycin, and Doxycycline.

The Mount Kenya University Ethical Review Committee (MKU/ERC/1649) approved the study and use of clinical samples on the 23<sup>rd</sup> of October 2020.


#### Data analysis

The mean, and SD values calculation, and graphs were done using Microsoft Excel (RRID:SCR\_016137) 2016. Probit regression analyses and calculation of the LLOD of *C. trachomatis*-IMRS and *C. trachomatis*-16S rRNA PCR assays (the concentration at which *Chlamydia trachomatis* DNA is determined with 95% confidence), was done in Excel 2016. *Trichomonas vaginalis* and *Treponema pallidum* DNA were used to confirm the specificity of the *C. trachomatis*-IMRS primers for other related infections. Analyses were done using paired *t*-test for two-tailed distribution. *P* < 0.05 was considered statistically significant.

## Results

#### Development and IMRS primer distribution targets on *Chlamydia trachomatis* genome

Using the IMRS-based genome mining algorithm<sup>10</sup>, six repeat sequences (Table 1)<sup>19,21</sup> were identified on the *Chlamydia trachomatis* genome, which could serve as reverse and forward primers for the PCR assay. The primers (F 5'- TGCTGCTGCT-GATTACGAGCCGA -3' and R 5'- TGTAGGAGGAGCCTCT-TAGAGAA -3'), as were depicted using a Circos plot version 0.69–9 (Circos; RRID:SCR\_011798) (Figure 1), are present



**Figure 1. *Chlamydia trachomatis*-IMRS primer targets and gel images from the *C. trachomatis* IMRS and conventional 16S rRNA PCR assay.** (A) Circos plot for the distribution of identical multi repeat sequence (IMRS) primers in the *C. trachomatis* genome. *C. trachomatis* IMRS primer A (blue lines) IMRS primer B (red lines) both have 6 repeats. (B) and (C) Gel image of 10-fold serially diluted (1 – 100, 2 – 10, 3 – 1, 4 – 0.1, 5 – 0.01, 6 – 0.001, 7 – 0.0001 and 8 – NTC) (pg/ $\mu$ l) genomic *C. trachomatis* DNA amplicons resolved on 1% gel using IMRS primers and gold standard 16S rRNA PCR primers, respectively.

at a number of loci allowing them to serve interchangeably as reverse or forward primers.

**Specificity of *C. trachomatis* identical multi-repeat primers**  
 To confirm specificity of the IMRS primers for regions on the *C. trachomatis* genome, serially diluted DNA was used as template for PCR amplification. The IMRS primers amplified *C. trachomatis* DNA at a starting template concentration of 0.1 fg/ $\mu$ L (Figure 1B), and the gold standard 16S rRNA primers (Figure 1C) detected *C. trachomatis* DNA to a concentration of 10 fg/ $\mu$ L. This shows that the IMRS-PCR assay has a 100-fold higher sensitivity compared to the conventional 16S rRNA PCR assay. Diluted *C. trachomatis* DNA was used as a template for real-time PCR amplification using *C. trachomatis*-IMRS primers (Table 2A), and conventional *C. trachomatis*-16S rRNA primers (Table 2B). Amplification curves were plotted using the mean Ct values at each respective dilution (Figure 2A, *C. trachomatis*-IMRS primers and Figure 2B, *C. trachomatis*-16S rRNA primers).

#### Determination of the Lower Limit of Detection (LLOD)

To calculate the lower limit of detection (LLOD) of the IMRS PCR and the conventional 16S rRNA PCR, probit statistic was

calculated using concentrations of 100 and 10 fold serially diluted *C. trachomatis* DNA and thereafter the dilutions served as starting template for the *C. trachomatis*-IMRS and 16S rRNA PCR respectively (Table 3A and Table 3B). The probit plots for the *C. trachomatis*-IMRS PCR and the gold standard 16S rRNA PCR assay are shown in Figure 3A and Figure 3B. The concentration at which *C. trachomatis* DNA can be estimated with 95% confidence was used to calculate the LLOD. Probit calculation for the *C. trachomatis*-IMRS PCR, had a coefficient of  $\chi = -3.6494$  and a *P*-value of 0.7043 (Table 4). As shown, the *C. trachomatis* IMRS primers had a detection limit of 9.5 fg/ $\mu$ L (Figure 3A). The probit calculation for the 16S rRNA PCR is shown in Table 4, and had a coefficient of  $\chi = -7.2101$  and a *P*-value of 0.9978. The 16S rRNA PCR assay for *C. trachomatis* had an LLOD of 4.31 pg/ $\mu$ L (Figure 3B). In summary, the *C. trachomatis*-IMRS PCR assay was more sensitive than the gold standard 16S rRNA PCR assay.

#### Genomic *Chlamydia trachomatis* DNA amplification using the Isothermal assay

Serially diluted genomic DNA was used to perform the Isothermal-*C. trachomatis*-IMRS amplification and the resulting reaction products visualized on a 1% gel (Figure 4A). The Isothermal-*C. trachomatis*-IMRS assay successfully amplified *C. trachomatis* DNA down to  $1.64 \times 10^2$  genome copies/ $\mu$ L. The LLOD for the *C. trachomatis*-Iso-IMRS assay was estimated at 0.3162 ng/ $\mu$ L (Figure 4C).

#### *Chlamydia trachomatis* Lateral Flow Assay

A visual readout signal was observed when serially diluted DNA was transferred on lateral flow assay (LFA) strips (Figure 4B). The LFA readout of the amplification products was successful indicating the potential and applicability of the Isothermal-IMRS assay in the field.

#### Plasmid *C. trachomatis*-DNA concentration in ng/ $\mu$ l of transformed *E. coli* cells

To validate the exact regions that were amplified by the *C. trachomatis*-IMRS primers, we cloned and transformed the amplicon into blunt vectors into electrocompetent *E. coli* cells, thereafter, the clones were plated on agar plates. Transformed cells were selected from eight colonies (Figure 5) and DNA extracted and sanger sequencing performed. Multiple sequence alignment confirmed *C. trachomatis* sequences. These shows that the *C. trachomatis*-IMRS primers are specific for targets within the *C. trachomatis* genome.

#### Validation of *C. trachomatis*-IMRS primers


*Chlamydia trachomatis* positive DNA samples from a cross-sectional study at the Kenyatta National Hospital were used to validate the *C. trachomatis*-IMRS primers for identifying *C. trachomatis* DNA using RT-PCR assay as indicated in Figure 6. The demographic information for recruited participants has been described in Table 5. Results from RT-PCR assay using *C. trachomatis*-IMRS primers were concordant

**Table 2. Genomic DNA dilution to determine the sensitivity of the *C. trachomatis*-IMRS primers using Real time PCR.** IMRS, identical multi-repeat sequences.

<b>A, Serially diluted <i>Chlamydia trachomatis</i> genomic DNA served as amplification templates for the <i>C. trachomatis</i>-IMRS primers</b>		
Concn of DNA (genome copies/ $\mu$ l)	Ct value	STD.DEV
$1 \times 10^4$	12.298	0.541
$1 \times 10^3$	17.674	1.244
$1 \times 10^2$	23.639	0.349
$1 \times 10^1$	28.265	0.275

<b>B, Serially diluted <i>Chlamydia trachomatis</i> genomic DNA served as amplification templates for the 16S rRNA primers</b>		
Concentration of DNA (genome copies/ $\mu$ l)	Ct value	STD.DEV
$1 \times 10^4$	14.64	0.902
$1 \times 10^3$	20.584	1.599
$1 \times 10^2$	26.607	1.056
$1 \times 10^1$	36.527	0.249



**Figure 2.** Real-time PCR amplification plots from the *Chlamydia trachomatis*-identical multi repeat sequence (IMRS) (A) and the 16S rRNA (B) assays using serially diluted *C. trachomatis* genomic DNA.

with the results from conventional PCR. The performance characteristics for the CT-IMRS PCR was as follows: sensitivity, 100% (95% CI, 79.41% - 100%) and specificity, 100% (95% CI, 79.41% - 100%)

#### Specificity and sensitivity of the *C. trachomatis*-IMRS primers

As indicated in Figure 7, *C. trachomatis*-IMRS primers showed specificity to *C. trachomatis* DNA and non-specific to *Trichomonas vaginalis* and *Treponema pallidum* genomic

DNA. Compared to the conventional 16S-rRNA PCR, the *C. trachomatis*-IMRS PCR accurately detected *C. trachomatis* genomic DNA at starting template concentration of 1 fg/ $\mu$ l (Figure 1B).

#### Discussion

Traditional techniques for identifying *C. trachomatis* infections are less sensitive, require collection of invasive patient samples, have complex algorithms and test result reporting, and are expensive<sup>17</sup>. As a consequence, there is need of developing

**Table 3.** *Chlamydia trachomatis* genomic DNA was serially diluted 100 folds (A) and 10-folds (B) and used as template for the *C. trachomatis*-IMRS and 16S rRNA PCR to estimate the lower limit of detection.


<b>A, 100-fold dilution</b>	
Serial dilutions (pg/μl)	Replicates (5)
100	5/5
1	5/5
0.01	4/5
0.0001	5/5
0.000001	0/5
0.00000001	0/5

<b>B, 10-fold dilution</b>	
Serial dilutions (pg/μl)	Replicates (5)
100	5/5
10	4/5
1	3/5
0.1	1/5
0.01	1/5
0.001	0/5

novel tests that are sensitive, specific and readily applicable in field set-ups. In the present study, we demonstrate the use of a deep genome mining strategy to identify identical multiple repeat sequences that could be used as robust primers for a novel nucleic acid-based test that is a highly sensitive test against *C. trachomatis*. Specifically, IMRS forward and reverse primers are able to initiate amplicon generation at various loci on the *C. trachomatis* genome. Therefore, the overall analytical sensitivity is improved by producing many amplicons<sup>22,23</sup>. Our findings confirm that, compared to the gold standard 16S rRNA PCR, using IMRS primers to amplify of specific sequences on the *C. trachomatis* genome is sensitive, yielding large number of amplicons of different sizes hence a lower detection limit of 9.5 pg/mL (8.4 genome copies/mL). Our results are comparable to the Chlamydial Roche Amplicor Real-Time Quantitative PCR with a lower limit of detection of 200 genome copies/ml<sup>24</sup>. However, this assay targets up to 10 copies of chlamydial plasmid.

We also confirmed that isothermal amplification of DNA using IMRS PCR primers is reliable and sensitive for detecting




**Figure 3.** Probit regression analysis to estimate the lower limit of detection for the *Chlamydia trachomatis*-identical multi repeat sequence (IMRS) primers and the 16S rRNA PCR. Probit analysis estimation for *C. trachomatis*-IMRS (**A**). As indicated, the IMRS primers for *C. trachomatis* had an LLOD = 9.5 pg/μl. **B:** Probit analysis estimation for 16S rRNA PCR. As indicated, gold standard primers for *C. trachomatis* had an LLOD = 4.31 pg/μl.

**Table 4.** Shows the statistics obtained from the Probit analysis. IMRS, identical multi-repeat sequences.

Assay	X Coefficient	P-Value
16S rRNA	-7.2101	0.9978
IMRS	-3.6494	0.7043

*C. trachomatis*. The *C. trachomatis*-Iso-IMRS assay detected DNA up to 8.9 genome copies per mL. The Isothermal-IMRS assay had increased sensitivity compared to a Loop-mediated isothermal assay utilizing the *ompA* and *orf1* genes, which reported a detection limit of 50 copies per mL<sup>25</sup>.

Our study had success in developing and testing a Lateral Flow Assay technology to detect *C. trachomatis* to a concentration of 10 pg/mL (8.8 genome copies/ml) (Figure 6). Our finding was different from a study that developed a visual read-out of



**Figure 4. *Chlamydia trachomatis*-Iso-identical multi repeat sequence (IMRS), lateral flow assay and estimation of the lower limit of detection of the isothermal assay.** (A) Gel image of *C. trachomatis*-Iso IMRS assay products visualized on 1% gel. Five replicates of each dilution served as DNA template for the *C. trachomatis*-Iso IMRS. DNA concentration is in genome copies per  $\mu$ l. (B) Visual read-out detection of serially diluted *C. trachomatis* DNA using the lateral flow assay. Amplicons were incubated at 65°C for 1 hour and transferred onto strips as indicated. IC – Internal Control, NTC – Non Template Control. (C) Probit analysis estimation for *C. trachomatis* Iso-IMRS. As indicated, the IMRS primers for *C. trachomatis* had an LLOD = 0.3162 ng/ $\mu$ l.


*C. trachomatis*-LAMP method based on a gold nanoparticle lateral flow biosensor that reported a limit of detection of 50 copies/ml after an incubation of 45 minutes<sup>26</sup>.

Compared to nucleic acid methods that are used for the identification of *C. trachomatis* that are mostly suboptimal, the *C. trachomatis*-IMRS PCR primers were specific and sensitive when used for the identification of *C. trachomatis* DNA.


The study limitation was the use of few clinical samples to validate the *C. trachomatis* IMRS PCR assay.

## Conclusions

Put together; here we show that the IMRS algorithm can serve as a platform technology for designing primers that are sensitive and specific for *C. trachomatis*. This platform has potential application in other bacterial and non-bacterial pathogens and could significantly improve future disease diagnostics procedures. The use of the *C. trachomatis* -IMRS primers when modified with fluorescent tags can be used to develop a visual



**Figure 5. Transformed *E.coli* cells expressing *Chlamydia trachomatis* sequences amplified using *C. trachomatis*-identical multi repeat sequence (IMRS) primers.**




**Figure 6.** Mean Ct values of PCR confirmed 16 clinical DNA samples from RT-PCR assay that were used to validate the *Chlamydia trachomatis*-identical multi repeat sequence (IMRS) PCR primers.

**Table 5. Demographic data for participants.**

Variable	Chlamydia positive, n = 16, (%)	Chlamydia negative, n = 187, (%)	P-Value
<i>Age Category</i>			
10 – 19	0, 0	2, 1	
20 – 29	6, 38	63, 34	0.9467
30 – 39	9, 56	105, 56	
40 – 49	1, 6	17, 9	
<i>Marital status</i>			
Married	13, 81	161, 86	0.5949
Not Married	3, 19	26, 14	
<i>Level of Education</i>			
Primary	1, 6	14, 7	
Secondary	8, 50	66, 35	0.5013
Tertiary	7, 44	107, 57	
<i>Employment status</i>			
Employed	8, 50	55, 29	0.0875
Not employed	8, 50	132, 71	
<i>Parity</i>			
Primipara	1, 6	39, 21	0.3702
Multipara	14, 88	138, 74	
Grandmultipara	1, 6	10, 5	
<i>Gestational Age</i>			
First trimester	0, 0	11, 6	0.0637
Second trimester	7, 44	37, 20	
Third trimester	9, 56	139, 74	

Variable		Chlamydia positive, n = 16,(%)	Chlamydia negative, n = 187, (%)	P-Value
HIV Status				
	Positive	1, 6	1, 1	
	Negative	15, 94	186, 99	0.0263
Miscarriage				
	None	9, 56	111, 59	
	Once	5	52, 28	
	Twice	2	14, 7	0.8421
	Thrice	0, 0	7, 11	
	Quadruple	0, 0	3, 2	



**Figure 7.** Gel image of PCR products obtained after amplification of *Treponema pallidum* (TP) and *Trichomonas vaginalis* (TV) genomic DNA using *Chlamydia trachomatis*-identical multi repeat sequence (IMRS) primers. *C. trachomatis* genomic DNA was used as a positive control. N = Negative control, L = Ladder.

read-out signal of DNA which can then be used in the design of a Lateral Flow Assay as has been described previously<sup>27</sup>.

## Data availability

### Underlying data

Zenodo: Chlamydia trachomatis RAW DATA. [https://zenodo.org/doi/10.5281/zenodo.10200809<sup>19</sup>](https://zenodo.org/doi/10.5281/zenodo.10200809).

GenBank: Chlamydia trachomatis D/UW-3/CX, complete genome. Accession number [https://identifiers.org.ncbi/insdc:AE001273.1<sup>21</sup>](https://identifiers.org.ncbi/insdc:AE001273.1).

Data are available under the terms of the [Creative Commons Attribution 4.0 International license \(CC-BY 4.0\)](#).

## Acknowledgements

We sincerely thank Dr. Karen Muthembwa and all staff working at the Sexually transmitted infection Clinic at the Kenyatta National Hospital, in Nairobi County.

An earlier version of this article can be found on medRxiv (doi: <https://doi.org/10.1101/2023.07.19.22272924>). An earlier version of the abstract can be found on scity (<https://scity.org/articles/activity/10.1101/2023.07.19.22272924>).

## References

- Wynn A, Mussa A, Ryan R, et al.: **Evaluating the diagnosis and treatment of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in pregnant women to prevent adverse neonatal consequences in Gaborone, Botswana: protocol for the Maduo study.** *BMC Infect Dis.* 2022; 22(1): 229. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Olaeye AO, Babah OA, Osuagwu CS, et al.: **Sexually transmitted infections in pregnancy - An update on *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.** *Eur J Obstet Gynecol Reprod Biol.* 2020; 255: 1–12. [PubMed Abstract](#) | [Publisher Full Text](#)
- Gadot A, Shannon CL, Hoff NA, et al.: **Prenatal chlamydial, gonococcal, and trichomonal screening in the Democratic Republic of Congo for case detection and management.** *Int J STD AIDS.* 2020; 31(3): 221–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Armstrong-Mensah E, Ebiringa DP, Whitfield K, et al.: **Genital Chlamydia Trachomatis infection: prevalence, risk factors and adverse pregnancy and birth outcomes in children and women in sub-Saharan Africa.** *Int J MCH AIDS.* 2021; 10(2): 251–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- World Health Organization: **Sexually transmitted infections.** 2019; 27: 9–10. [Reference Source](#)
- Budai I: ***Chlamydia trachomatis*: Milestones in clinical and microbiological diagnostics in the last hundred years: a review.** *Acta Microbiol Immunol Hung.* 2007; 54(1): 5–22. [PubMed Abstract](#) | [Publisher Full Text](#)
- Meyer T: **Diagnostic procedures to detect *Chlamydia trachomatis* infections.** *Microorganisms.* Multidisciplinary Digital Publishing Institute (MDPI); 2016; 4(3): 25. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Böhm I, Gröning A, Sommer B, et al.: **A German *Chlamydia trachomatis* screening program employing semi-automated real-time PCR: results and perspectives.** *J Clin Virol.* 2009; 46 Suppl 3: S27–32. [PubMed Abstract](#) | [Publisher Full Text](#)
- Elnifro EM, Storey CC, Morris DJ, et al.: **Polymerase chain reaction for detection of *Chlamydia trachomatis* in conjunctival swabs.** *Br J Ophthalmol.* 1997; 81(6): 497–500. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Watson EJ, Templeton A, Russell I, et al.: **The accuracy and efficacy of screening tests for *Chlamydia trachomatis*: A systematic review.** *J Med Microbiol.* Lippincott Williams and Wilkins; 2002; 51(12): 1021–31. [PubMed Abstract](#) | [Publisher Full Text](#)
- Masek BJ, Arora N, Quinn N, et al.: **Performance of three nucleic acid amplification tests for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* by use of self-collected vaginal swabs obtained via an internet-based screening program.** *J Clin Microbiol.* 2009; 47(6): 1663–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Papp JR, Schachter J, Gaydos CA, et al.: **Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* - 2014.** *MMWR Recomm Rep.* 2014; 63(RR-02): 1–19. [PubMed Abstract](#) | [Free Full Text](#)
- Lanjouw E, Ouburg S, de Vries HJ, et al.: **2015 European guideline on the management of *Chlamydia trachomatis* infections.** *Int J STD AIDS.* 2016; 27(5): 333–48. [PubMed Abstract](#) | [Publisher Full Text](#)
- CDC: **MMWR Chlamydia testing. Guidelines.** 2002; 51: 48.
- de Haro-Cruz MJ, Guadarrama-Macedo SI, López-Hurtado M, et al.: **Obtaining an ELISA test based on a recombinant protein of *Chlamydia trachomatis*.** *Int Microbiol.* 2019; 22(4): 471–8. [PubMed Abstract](#) | [Publisher Full Text](#)
- Bianchi S, Frati ER, Canuti M, et al.: **Molecular epidemiology and genotyping of *Chlamydia trachomatis* infection in a cohort of young asymptomatic sexually active women (18–25 years) in Milan, Italy.** *J Prev Med Hyg.* 2016; 57(3): E128–34. [PubMed Abstract](#) | [Free Full Text](#)
- Shetty S, Kouskouti C, Schoen U, et al.: **Diagnosis of *Chlamydia trachomatis* genital infections in the era of genomic medicine.** *Braz J Microbiol.* Brazilian Society of Microbiology; 2021; 52(3): 1327–39. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Raju LS, Kamath S, Shetty MC, et al.: **Genome mining-based identification of identical multirepeat sequences in *Plasmodium falciparum* genome for highly sensitive real-time quantitative PCR assay and its application in malaria diagnosis.** *J Mol Diagn.* 2019; 21(5): 824–38. [PubMed Abstract](#) | [Publisher Full Text](#)
- Shiluli C: ***Chlamydia trachomatis* RAW DATA.** Zenodo. [Dataset]. 2023. <http://www.doi.org/10.5281/zenodo.10200810>
- Graham EK, Drobac J, Thompson J, et al.: **Evaluation of the PowerQuant® System on the QuantStudio™ 5 Real-Time PCR System.** White Pap Promega Corp; 2018; 1–12. [Reference Source](#)
- Stephens RS, Kalman S, Lammel CJ, et al.: ***Chlamydia trachomatis* D/UW-3/CX, complete genome.** GenBank. [Dataset]. 2014. <https://identifiers.org.ncbi/insdc:AE001273.1>
- Balows A: **Manual of clinical microbiology 8th edition.** *Diagn Microbiol Infect Dis.* 2003; 47(4): 625–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- Kulkarni S, Bala M, Risbud A: **Performance of tests for identification of *Neisseria gonorrhoeae*.** *Indian J Med Res.* 2015; 142(6): 833–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wiggins R, Graf S, Low N, et al.: **Real-time quantitative PCR to determine chlamydial load in men and women in a community setting.** *J Clin Microbiol.* 2009; 47(6): 1824–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chen X, Zhou Q, Yuan W, et al.: **Visual and rapid identification of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using multiplex loop-mediated isothermal amplification and a gold nanoparticle-based lateral flow biosensor.** *Front Cell Infect Microbiol.* 2023; 13: 1067554. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chen X, Zhou Q, Tan Y, et al.: **Nanoparticle-Based lateral flow biosensor integrated with loop-mediated isothermal amplification for rapid and visual identification of *Chlamydia trachomatis* for point-of-care use.** *Front Microbiol.* 2022; 13: 1914620. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Peters RPH, Klausner JD, Mazzola L, et al.: **Novel lateral flow assay for point-of-care detection of *Neisseria gonorrhoeae* infection in syndromic management settings: a cross-sectional performance evaluation.** *Lancet.* 2024; 403(10427): 657–664. [PubMed Abstract](#) | [Publisher Full Text](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 21 May 2024

<https://doi.org/10.21956/openresafrica.16048.r31268>

© 2024 Awandu S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Shehu Awandu** 

Jaramogi Oginga Odinga University of Science and Technology, Bondo, Kenya

The authors have adequately responded to my comments

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

## Version 1

Reviewer Report 23 March 2024

<https://doi.org/10.21956/openresafrica.15473.r30839>

© 2024 Were T. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Tom Were** 

Masinde Muliro University of Science and Technology, Kakamega, Kakamega County, Kenya

**Summary:**

The study developed a highly sensitive molecular method based on de novo genome mining to detect multi-repeat sequences (IMRS) in *C. trachomatis* genome for isothermal amplification and PCR assays. The IMRS identified 6 repeat sequences that generated forward and reverse sequence primers for PCR yielding amplicons of 137-440bp. The primers also had high ct values at amplification of 16s rRNA in serially diluted ( $1 \times 10^4$ - $1 \times 10^1$ ) genomic DNA copies. The study also

identified that the primers gave a lower limit of detection of 0.001 pg/ml at 100-fold, and 0.01 at 10-fold genomic DNA dilution. In addition, cloning validation experiments indicated that the primers had a LLOD of 9.5 fg/ml vs. gold standard of 4.5 pg/ml. Specificity and sensitivity evaluations show that the primers were specific for *Chlamydia vaginalis* bacteria. However, it is important that the authors add specificity and sensitivity chi-square calculations. The study identified and validated through IMRS-technology and PCRs primers with potential for detection of *C. trachomatis* infections in patients.

Additional comments:

- Paragraph #1: line 10-14 – also add the fact that *C. trachomatis* is a major cause of infertility through blocked fallopian tubes.
- Paragraph #4-6, should be moved to after paragraph #10 with line 8-18 of current paragraph #10 moving to the new paragraph #10.
- Specify the number of clinical samples used in the validation of the assay
- Methods – page 4, line 24: indicate the target/band sizes
- Methods – page 4, line 41: interchange the order of reverse and forward primers as well as in line 53
- Methods – indicate the source of ethidium bromide in the whole chapter
- Table 5 is not described in the text
- Discuss the limitations of the study
- In the conclusion you state that the primers were sensitive and specific, yet sensitivity and specificity including AUC were not analyzed.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Infectious diseases; genetics; laboratory medicine; and immunology

**I confirm that I have read this submission and believe that I have an appropriate level of**

expertise to confirm that it is of an acceptable scientific standard.

Author Response 28 Apr 2024

**Jesse Gitaka**

Professor Tom Were, Department of Microbiology, School of Medicine, Masinde Muliro University of Science and Technology, Kakamega, Kenya 20<sup>th</sup> April 2024 **Rebuttal Submission for Research article titled “Multi-repeat sequences identification using genome mining techniques for developing highly sensitive molecular diagnostic assay for the detection of *Chlamydia trachomatis*”** We were delighted to receive comments on our submitted manuscript. Below is a structured response to the comments.

**1. Paragraph #1: line 10-14 – also add the fact that *C. trachomatis* is a major cause of infertility through blocked fallopian tubes.**

We have included the suggested adverse outcome of *C. trachomatis* infection in the submitted version 2 of the manuscript. (Line 7)

**1. Paragraph #4-6, should be moved to after paragraph #10 with line 8-18 of current paragraph #10 moving to the new paragraph #10.**

In the submitted version of the manuscript, the paragraphs have been changed accordingly.

**1. Specify the number of clinical samples used in the validation of the assay**

The number of clinical samples that were used in the validation of the IMRS assay has been included in the submitted manuscript. Line 341

**1. Methods - page 4, line 24: indicate the target/band sizes**

The target size and regions of the *C. trachomatis* IMRS primers has been included appropriately. Line 100.

**1. Methods - page 4, line 41: interchange the order of reverse and forward primers as well as in line 53**

The order of the reverse and forward primer has been interchanged as recommended.

**1. Methods - indicate the source of ethidium bromide in the whole chapter**

The source of ethidium bromide has been included in the submitted version of the manuscript. Line 124, 138 and 149.

**1. Table 5 is not described in the text**

Table 5 has been cited in the main manuscript. Line 336

**1. Discuss the limitations of the study**

Limitation of the study has been highlighted in the submitted version of the manuscript. Line 386

**1. In the conclusion you state that the primers were sensitive and specific, yet sensitivity and specificity including AUC were not analyzed.**

The lower limit of detection was used to compute the sensitivity of the *C. trachomatis* IMRS assay. When compared with the conventional 16S rRNA PCR, the primers were sensitive. Also *C. trachomatis* IMRS PCR assay mean AUC values were higher. To determine the specificity of the *C. trachomatis* IMRS primers, we used genomic DNA from *Trichomonas vaginalis* and *Treponema pallidum*. As expected, no amplification was observed.

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 01 March 2024

<https://doi.org/10.21956/openresafrica.15473.r30594>

© 2024 Awandu S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

? Shehu Awandu 

Jaramogi Oginga Odinga University of Science and Technology, Bondo, Kenya

Describe the advantages of the new techniques besides sensitivity. Turn around time? Indicate, qPCR assay efficiency etc. Specific treatment offered to the infected patients. Figure 1 B & C are incomplete. PCR bands are fuzzy, were assays optimised? Show sensitivity and specificity in % when compared to the gold standard.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 17 Mar 2024

Jesse Gitaka

Dear Dr. Shehu Awandu, Jaramogi Oginga Odinga University of Science and Technology 17<sup>th</sup> March 2024 **Rebuttal Submission for Research article titled "Multi-repeat sequences**

**identification using genome mining techniques for developing highly sensitive molecular diagnostic assay for the detection of *Chlamydia trachomatis*"** We were delighted to receive your comments on our submitted manuscript. Below is a structured response to the comments.

**1. Describe the advantages of the new techniques besides sensitivity.**

Indeed, in addition to increased sensitivity, the CT-IMRS PCR assay is also specific to *Chlamydia trachomatis* DNA. The CT-IMRS PCR has the potential of being developed into a lab on a chip device with the capability of being deployed in resource limited set-ups. A paragraph describing how this can be achieved has been included in page 12 in the revised manuscript (367-370).

**1. Turn around time?**

Our research has demonstrated the application of the CT-IMRS PCR primers for isothermal amplification of *Chlamydia trachomatis* DNA and CT-Lateral Flow Assay. The turn-around time for the isothermal assay is 40 minutes and the Lateral Flow Assay is 1 hour, the CT-IMRS PCR lasts for 1hr 18 minutes. This however does not include DNA extraction and gel visualization. The Real time PCR assay using CT IMRS primers has a turn around time of 1 hour. This has been described in the method section; Line 114 and Line 126

**1. Indicate, qPCR assay efficiency etc.**

The PCR efficiency was within the recommended values.

**1. Specific treatment offered to the infected patients.**

Participating patients were on routine Antenatal Care, pregnant women with suspected STI symptoms such as vaginal and urethral discharge, lower abdominal pain, were treated syndromically by qualified clinicians. Patients with persistent symptoms were referred to a molecular laboratory for testing. The following drugs were used, Ceftriaxone, Azithromycin, and Doxycycline. This is indicated in the revised manuscript, Line 203 and 204.

**1. Figure 1 B & C are incomplete.**

The captions for Fig 1B and C have been appropriately rephrased as shown in the revised version of the manuscript. Line 227.

**1. PCR bands are fuzzy, were assays optimised?**

Indeed, the CT-IMRS assays were optimized. The CT-IMRS primers are specific for 6 targets on the genome. As shown in Table 1, the expected fragments differ in base pair size and therefore the smearing pattern seen on the PCR gel is expected. Published research on *Plasmodium falciparum* IMRS have also reported similar findings.

<https://doi.org/10.1016/j.jmoldx.2019.04.004>

**1. Show sensitivity and specificity in % when compared to the gold standard.**

Nucleic Acid Amplification Tests, are considered the gold standard for diagnosing chlamydia infection. For this specific reason, we determined the performance characteristics of the CT-IMRS assay. We have included the percentages of the sensitivity and specificity in the revised version of the manuscript. Line 320 and 321.

**Competing Interests:** No competing interests